Core Insights - Viatris Inc. reported second-quarter 2025 adjusted earnings of 62 cents per share, exceeding the Zacks Consensus Estimate of 56 cents, but down from 69 cents per share in the same quarter last year [1][7] - Total revenues for the quarter were $3.58 billion, a decrease of 6% year over year, yet surpassing the Zacks Consensus Estimate of $3.5 billion [1][5] - The company's share price has declined 29.7% year to date, compared to an 8.6% decline in the industry [2] Revenue Breakdown - Sales from Developed Markets were $2.11 billion, down 4% on a divestiture-adjusted operational basis, but above the Zacks Consensus Estimate of $2.01 billion [5] - Emerging Markets generated sales of $555.1 million, up 1% on a divestiture-adjusted operational basis, beating the Zacks Consensus Estimate of $542 million [6] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $305.7 million, down 11% on a divestiture-adjusted operational basis, missing the Zacks Consensus Estimate of $310 million [6] - Greater China sales reached $588.9 million, up 9% on a divestiture-adjusted operational basis, exceeding the Zacks Consensus Estimate of $546 million [6] Product Category Performance - Revenues from Brands decreased 3% to $2.3 billion, but increased 3% on a divestiture-adjusted operational basis, driven by strong performance in Greater China and Emerging Markets [7] - Lipitor sales rose to $388 million, Norvasc sales increased to $182.7 million, and Lyrica sales grew to $128.1 million compared to the previous year [8] - Generics revenues were $1.28 billion, down 10%, with a 9% decline on an operational change basis, attributed to the negative impact from the Indore facility [9] Financial Metrics - Adjusted gross margin was 56.3%, down from 58.4% in the prior year [11] - The company has returned over $630 million to shareholders in the year to date, including more than $350 million in share repurchases [11] - Viatris expects total share repurchases of $500 million to $650 million in 2025 [11] Guidance and Updates - The company reaffirmed its 2025 revenue guidance of $13.5 billion to $14 billion and raised its adjusted earnings per share forecast to a range of $2.16 to $2.30 [12] - Positive top-line results were announced from phase III studies evaluating MR-142 and MR-141 for treating vision impairments [13] - A phase III study for MR-139 did not meet its primary endpoint [14]

Core Viewpoint - Viatris Inc. (VTRS) reported better-than-expected first-quarter adjusted earnings of 50 cents per share, surpassing the Zacks Consensus Estimate of 49 cents, although down from 67 cents per share in the same quarter last year [1][15] Financial Performance - Total revenues for the quarter were $3.25 billion, reflecting an 11% year-over-year decline, but still exceeding the Zacks Consensus Estimate of $3.23 billion [1][15] - Adjusted gross margin decreased to 55.9% from 58.8% year-over-year [10] Sales Breakdown - Sales from Developed Markets were $1.9 billion, down 3% on a divestiture-adjusted operational basis, missing the Zacks Consensus Estimate of $1.93 billion [4] - Emerging Markets generated $519.9 million in sales, down 5% on a divestiture-adjusted operational basis, but beating the Zacks Consensus Estimate of $464 million [5] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $276.1 million, down 6% and missing the Zacks Consensus Estimate of $309 million [5] - Greater China sales increased by 4% to $555.5 million, surpassing the Zacks Consensus Estimate of $553 million [5] Product Category Performance - Revenues from Brands decreased by 8% to $2.1 billion, but increased by 3% on a divestiture-adjusted operational basis [6] - Lipitor sales were $388 million, relatively flat year-over-year, while Norvasc and Lyrica sales declined [6] - Generics revenue was $1.1 billion, down 16%, with an operational decline of 11% [7][9] Future Guidance - Viatris maintains its total revenue guidance for 2025 at $13.5-$14 billion and adjusted earnings per share guidance at $2.16-$2.30, updated from a previous range of $2.12-$2.26 [12] Research and Development Updates - Positive results were reported from phase III studies for Effexor and a novel formulation of meloxicam, with plans to submit a new drug application to the FDA by the end of 2025 [13][14]

Core Viewpoint - Pfizer has experienced significant stock price declines since its peak in late 2021, primarily due to reduced sales of its COVID-19 treatments and vaccines, but it still holds potential for future growth, particularly in oncology and offers an attractive dividend yield [2][4][5] Group 1: Stock Performance - Pfizer's stock has seen over a 60% decline from its late-2021 high, with a $10,000 investment from 10 years ago now worth just over $7,000 [2] - Including reinvested dividends, the investment would be worth approximately $10,600 over the same period, although this still lags behind broader market returns [3] Group 2: Sales and Market Reaction - The decline in stock value is largely attributed to slowing sales of its COVID-19 treatment Paxlovid and vaccine Comirnaty, with no compensating growth from other products in its portfolio [4] Group 3: Future Outlook - Despite recent setbacks, there are new growth prospects for Pfizer, especially in oncology, and the stock's forward-looking dividend yield of 7.5% may attract new investors confident in the company's future [5]